MoonLake https://validator.w3.org/feed/docs/rss2.html Homepage VP Marketing Manager IT Data Integration & Platforms Senior Director Analytics, Performance and Forecasting Senior Specialist Drug Product and Device (GxP) Senior Specialist/ Associate Manager, Medical Affairs (Fixed-Term Contract) Strategy, Contracting & Pricing Lead Payer Account Team Lead MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 BTIG Annual Biotechnology Conference, Virtual Leerink Partners Therapeutics Forum: I&I and Metabolism VP Market Access & Pricing Senior Specialist Contract Management, AI & Compliance Careers Manager Clinical Operations Director / Senior Director Payer Marketing MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting Pipeline Associate Manager Payroll and Employee Benefits Finance About us MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day Director Insights & Performance Analytics MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering Privacy Policy & Cookie Notice Privacy Notice for Healthcare Professionals Contact us MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab Therapeutic Focus Header – Test MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update Science Psoriatic arthritis (PsA) Psoriasis (PsO) Palmoplantar pustulosis (PPP) Hidradenitis suppurativa (HS) Axial Spondyloarthritis (axSpA) Do you still antibody? Do you still antibody? It’s all about the dimers! Martin Yateman Eva Cullen Aileen Desonglo